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Broad and potent cross clade 
neutralizing antibodies with 
multiple specificities in the plasma 
of HIV-1 subtype C infected 
individuals
Narayanaiah Cheedarla1, K. Lucia Precilla1, Hemalatha Babu1, K. K. Vidya Vijayan1, 
Manickam Ashokkumar1, Padmapriyadarsini Chandrasekaran1, Nandagopal Kailasam2, 
Jagadish Chandrabose Sundaramurthi1, Soumya Swaminathan1, Viswanath Buddolla3, 
S. Kalyanaraman Vaniambadi4, V. D. Ramanathan1 & Luke Elizabeth Hanna1
Broadly Cross clade Neutralizing (BCN) antibodies are recognized as potential therapeutic tools and 
leads for the design of a vaccine that can protect human beings against various clades of Human 
Immunodeficiency Virus (HIV). In the present study, we screened plasma of 88 HIV-1 infected ART naïve 
individuals for their neutralization potential using a standard panel of 18 pseudoviruses belonging to 
different subtypes and different levels of neutralization. We identified 12 samples with good breadth 
of neutralization (neutralized >90% of the viruses). Four of these samples neutralized even the 
difficult-to-neutralize tier-3 pseudoviruses with great potency (GMT > 600). Analysis of neutralization 
specificities indicated that four samples had antibodies with multiple epitope binding specificities, viz. 
CD4-binding site (CD4BS), glycans in the V1/V2 and V3 regions and membrane proximal external region 
(MPER). Our findings indicate the strong possibility of identifying highly potent bNAbs with known 
or novel specificities from HIV-1 subtype C infected individuals from India that can be exploited as 
therapeutic tools or lead molecules for the identification of potential epitopes for design of a protective 
HIV-1 vaccine.
An important goal of Human Immunodeficiency Virus (HIV) research is the development of a vaccine that can 
elicit highly potent broadly neutralizing antibodies (bNAbs) such as those seen in some of the HIV-infected indi-
viduals who are able to partly control HIV infection1,2. During the acute stage of HIV infection, most individuals 
develop non-neutralizing antibodies (n-NAbs) that bind primarily to non-functional envelopes and may mediate 
antiviral activity through Antibody Dependent Cellular Cytotoxicity (ADCC) or Antibody mediated Cellular 
Phagocytosis (ADCP). About 10–30% of chronically infected individuals are reported to produce bNAbs over a 
period of time, that are capable of blocking HIV infection through neutralization3–5. The sole target for bNAbs 
is the envelope (Env) on the surface of HIV that helps the virus to infect the host cell. Broadly neutralizing anti-
bodies are categorized into five types based on their target sites on the HIV envelope, viz. CD4 binding site (HJ16, 
NIH45-46, VRC01-03, VRC06, 3BNC117 etc.), N160 glycan in the V2 apex (PG9, PG16, CAP256-VRC26), N332 
glycan at the base of the V3 loop (PGT121, PGT128), gp120-gp41 interface (8ANC195, PGT151 and 35022) and 
the membrane proximal external region (MPER) (10E8)6. High genetic diversity and presence of glycan shield in 
the HIV Env constitute major hurdles for the development and function of bNAbs7.
Several research groups have identified and characterized a number of bNAbs with great breadth and potency 
employing advanced immunological techniques8–11. In the recent years, a number of bNAbs capable of strongly 
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neutralizing HIV-1 clade C strains have also been identified12. HIV-1 subtype C is the predominant strain in the 
HIV epidemic and is responsible for > 50% of infections worldwide and > 90% of infections in India (UNAIDS 
2016 and NACO 2016), and therefore, identification of more bNAbs that can strongly neutralize HIV-1 subtype 
C viruses is a global priority. In the present study, we screened plasma of 88 HIV-1C infected individuals to 
identify broadly neutralizing antibodies with good breadth and potency and characterized their neutralization 
specificities.
Results
Clinical profile of study subjects. The study population comprised of 101 HIV-1 infected ART naïve indi-
viduals (41 males, 59 females, 1 transgender), aged between 22 and 53 years. Most individuals (n = 65) had CD4+ 
T cell counts > 350 cells/mm3 (median 500 cells/mm3). CD4+ T cell count could not be performed on 4 samples 
due to sample lysis. Viral load was estimated using the COBAS Amplicor HIV-1 Monitor v1.5 and found to range 
between 400–750,000 copies/ml (median 26,212 copies/ml). Table 1 provides the demographic details and clinical 
profile of the study participants; complete clinical and immunological data are provided as a Supporting Table 
(Table S1).
Neutralization of plasma samples. Thirteen samples were excluded from testing either due to insufficient 
sample volume or due to very recent infection. The remaining 88 plasma samples were screened for HIV-1 neu-
tralization activity against a panel of 6 tier-1 pseudoviruses listed in Supplementary Table 2 (Table S2). Fifty eight 
samples were found to neutralize 4 or more of the viruses, and eight neutralized all the 6 pseudoviruses. > 60% 
neutralization was considered as good breadth of neutralization as defined by Montefiori (2005). The 58 samples 
were further tested against a panel of six tier-2 pseudoviruses. Thirty plasma samples were found to neutralize 4 
or more pseudoviruses, and six of them neutralized all the 6 pseudoviruses. The 30 samples were screened with 
a panel of six tier-3 pseudoviruses. Twelve samples , namely NAB001, NAB004, NAB016, NAB033, NAB046, 
NAB059, NAB062, NAB063, NAB065, NAB069, NAB120 and NAB122 neutralized 4 or more pseudoviruses; 
hence they were considered as broadly cross-clade neutralizing (BCN) samples. The results of the neutralization 
assay are provided in Table S2 and the heat maps of neutralization activity against the 3 panels of the pseudovi-
ruses are provided as Supplementary Figs S1, S2 and S3.
Potency of neutralization of BCN samples. The neutralization titration assay was performed for 10 of 
the 12 BCN samples with a panel of 7 tier 3 pseudoviruses listed in Table 2 (two samples were titrated with one 
or two pseudoviruses only due to insufficient sample volume). The ID50 was calculated through a dose-response 
curve fit with non- linear function using GraphPad prism5.0 (Fig. 1). Geometric mean titer (GMT) was calculated 
for each plasma against all the tier-3 pseudoviruses (Table 2). Four plasma samples (NAB001, NAB059, NAB063 
and NAB069) neutralized all the tier-3 pseudoviruses with GMT > 400 and had ID50 values > 50. The GMT of the 
remaining samples (NAB016, NAB033, NAB046, NAB062, NAB065 and NAB120) ranged between 100 and 400. 
Thus, most of the BCN samples tested exhibited high potency for neutralization.
Antibodies to linear peptides of 93IN101gp160. The BCN samples were tested in an ELISA with linear 
peptides spanning the full length envelope protein of the Indian HIV-1 subtype C clone 93IN101, in order to 
identify the binding specificities of the antibodies in the plasma. Eleven BCN samples were used for this analysis 
(one sample could not be tested due to insufficient volume). All 11 samples had antibodies that bound to the V3 
loop and Immunodominant (ID) region of gp41. Three samples had antibodies that bound to the MPER peptides 
(Fig. 2). Some of the BCN samples exhibited binding activity to discontinuous epitopes spread across the HIV 
Env Gp160. None of the samples had antibodies against the Cytoplasmic tail (CT) of the HIV-1 envelope.
CD4 binding site (CD4BS) antibodies. The 12 BCN plasma samples were screened for the presence of 
CD4BS antibodies using the recombinant CD4BS protein RSC3 and its mutant form RSC3∆ 371I/P363N. Four 
samples (NAB033, NAB059, NAB063 and NAB069) had varying amounts of RSC3 directed CD4BS antibodies 
(55, 40.2, 32.3 and 91% respectively), as indicated by their ability to bind selectively to the wild type protein but 
not to the mutant form (i.e., difference in binding activity between RSC3 and RSC3∆ 371I/P363N was signifi-
cant, p < 0.05). RSC3 specific IgG was eluted from these four samples and binding activity was compared with 
Samples (n = 101)*
CD4+ T cells/mm3
>350 250–350 <250
65 21 11
Sex
Men 21 10 9
Women 43 11 2
Transgender 1
Age (Mean± SD) in years 30.5 ± 5.5 34.04 ± 7.43 42.09 ± 9.43
Median Viral Load  
(IQR), copies/ml
26,212  
(3,297–77,200)
70,200  
(11,570–229,500)
94,500  
(41,400–408,000)
Table 1.  Clinical and Demographic profile of HIV-1 infected individuals in this study. A total of 101 
samples were collected for the study; of these 4(*) could not be tested for CD4 count at the time of sample 
collection and hence not included in the above Table.
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that of well characterized MAbs such as VRC01, VRC03, b12 and 3BNC117 (Fig. 3A,B and Table 3). Further, 
neutralization titer assay was performed for RSC3-specific IgG eluted from the four BCN plasma samples with a 
VRC01- resistant and sensitive pseudovirus (DU422 and CAP45.2.00), a sensitive and resistant tier-2 pseudovirus 
(JR-FL wild type and JR-FL mutant D279A), as well as a tier-3 pseudovirus (PVO-4). Known CD4BS monoclo-
nal antibodies VRC01 and b12, were used as positive controls. The known CD4BS antibodies showed stronger 
Sample 
ID
Tier-3 pseudo viruses
Subtype-B viruses CRF02_AG viruses Control
GMTPVO-4 TRJO4551.58 33-7 33-7 253-11 257-31 278-50 MuLV#
NAB001 2731 6362 1430 491.7 876.8 115 93.25 < 20 734
NAB004* ND ND 103.1 ND ND ND ND ND NA
NAB016 9457 1065 941.5 120 116.2 76.15 138.7 < 20 391
NAB033 417.1 363.7 506.3 220.8 64.07 149.3 275.1 < 20 239
NAB046 69.6 2348 840.5 62.4 50.08 120 144.3 < 20 185
NAB059 11016 2062 8225 427.5 600 49.48 1271 < 20 1170
NAB062 156.7 3029 929.3 49.73 1146 53.14 50.69 < 20 253
NAB063 14915 927.2 365.8 175.1 718 165.3 1174 < 20 741
NAB065 855 268.1 361.6 296.8 136.6 75.25 100 < 20 220
NAB069 5760 251 360 193.8 3060 591.4 402 < 20 688
NAB120 47.04 114.1 540 262.3 1902 540 714.2 < 20 343
NAB122* 95.43 234.4 ND ND ND ND ND ND NA
Table 2.  Neutralization titration (ID50) analysis of 12 BCN plasma samples. Plasma ID50 values are 
formatted as follows: italic format, ID50 500–999 and bold format, ID50 ≥ 1000. This experiment was done in 
duplicate on two independent occasions. ND- Not Done; NA- Not Applicable. *Excluded for GMT calculations. 
#MuLV, murine leukemia virus control.
Figure 1. Neutralization potency of 12 BCN plasma samples. Neutralization titration (1:20 to 1:43740) 
analysis was performed against 7 tier-3 pseudoviruses in TZM-bl cells. Most of the BCN plasma were able to 
neutralize tier-3 pseudoviruses which are highly resistant to neutralization with high efficiency as seen by the 
high ID50 values.
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neutralization of the wild type (sensitive) viruses than IgG eluted from BCN samples as the former were monoclo-
nal and the latter were polyclonal in nature. Two BCN plasma samples (NAB069 and NAB063) strongly neutral-
ized JR-FL WT (IC50 at 1.18 and 1.28 μ g/ml respectively) but not the mutant JR-FL D279A, while NAB059 weakly 
neutralized JR-FL WT (IC50 at 9.1 μ g/ml). NAB069, NAB063 and NAB033 neutralized tier-3 HIV-1 subtype B 
pseudovirus PVO-4 at > 5 μ g/ml. NAB069 alone neutralized CAP45.2.00 virus at 9 μ g/ml (Fig. 3C and Table 4).
Antibodies targeting glycans at positions 160 and 332 on the gp120 trimer. Neutralization assay 
was performed for 8 of the 12 BCN samples, for which sufficient volume of plasma was available, with a wild type 
tier-2 HIV-1 subtype C virus (DU156), and its mutant forms (DU156N160K and DU156N332A). All 8 samples 
showed strong neutralization activity against DU156WT (Fig. 4A, Table 5). Four samples showed significantly 
lower levels of neutralization of DU156N160K; neutralization activity of one sample (NAB062) was 25 fold lower 
with the DU156N160K mutant as compared to DU156WT, but < 3 fold with the other three samples (NAB016, 
NAB033 and NAB069). The remaining four samples (NAB046, NAB059, NAB063 and NAB065) showed a higher 
level of neutralization of DU156N160K than the WT virus, indicating that antibodies in these samples do not 
specifically target N160 glycan but target other regions of the HIV-1 Env.
The four samples (NAB016, NAB033, NAB062 and NAB069) that showed varying levels of dependence on 
N160 glycan were further studied to understand whether the glycan dependent antibodies in these individuals 
were similar to those belonging to the PG9/PG16 series by performing neutralization assay. It is known from liter-
ature that PG9/PG16 bNAbs do not neutralize the HIV-1 subtype B JR-FL WT strain due to presence of glutamic 
acid (E) at 168 position. However, when E is replaced with lysine (K) in the WT JR-FL strain by single mutation, it 
turned sensitive to neutralization by PG9/PG16 antibodies13. We therefore used these two pseudoviruses (JR-FL 
WT and JR-FL E168K) for further analysis of PG9/PG16 like bNAbs. Four samples strongly neutralized (> 3 fold) 
the mutant pseudovirus than the JR-FL WT (Fig. 4B and Table 6). Neutralization was also performed for the 
identification of positional dependence using two double mutants JR-FL E168K N156K and JR-FL E168K N160K 
(Fig. 4C). Three of the four samples (NAB016, NAB062 and NAB069) showed reduced neutralization of both 
double mutants (3–5 fold reduction) as compared to the single mutant (Table 7). One sample (NAB033) showed 
< 3 fold reduction in neutralization of both the double mutants.
Further, we also observed lower levels of neutralization of the mutant virus, DU156N332A, by seven of the 
eight BCN samples as compared to DU156WT; the decrease was > 3 fold in three samples (NAB046, NAB062 
and NAB069) and 1.5–2.5 fold in four samples (NAB016, NAB033, NAB059 and NAB065). NAB062 showed the 
maximum reduction in neutralization of 24.3 fold as compared to the WT DU156 (Table 5).
MPER specific neutralizing antibodies. To identify MPER-specific neutralizing antibodies, we selected 
three plasma samples NAB069, NAB120 and NAB122 which showed binding to overlapping MPER peptides in 
the initial PepScan analysis (Fig. 2). None of the three samples neutralized HIV-2 7312A strain (Table 8). NAB069 
showed a 1.5 fold higher titer for neutralization of chimeric virus containing the subtype B MPER (C1) as com-
pared to the one containing the subtype C MPER (C1C), suggesting the presence of 2F5, 4E10 or Z13e1-like 
neutralizing antibodies. In contrast, for NAB122, there was a significant drop in ID50 value with virus containing 
the subtype C MPER as compared to the one containing the subtype B MPER. However, the two plasma samples 
(NAB069 and NAB122) neutralized C6 strain which recognizes the 4E10 epitope, WFDIT, which is present in 
both subtypes B and C. NAB120 did not neutralize any of the chimera viruses.
It is reported that neutralization of MPER chimera viruses need not necessarily result in neutralization of 
HIV-1 primary isolates, since HIV-2/HIV-1 chimera viruses are more sensitive to the 4E10 and Z13e1 MAbs than 
HIV-1 primary isolates14. Therefore, to evaluate further the neutralization ability of NAB069 and NAB122 plasma, 
we eluted polyclonal IgG from these samples using pIndie full length MPER peptide coated tosyl-activated 
Figure 2. Linear PepScan of 93IN101 gp160. Total of 192 peptides, 15 amino acid long with 11 amino acid 
overlapping sequence covering the entire 93IN101 envelope (gp160) protein were used. Plasma samples (n = 11) 
from BCN samples were tested at a dilution of 1:50 for the identification of binding reactivity. Healthy Human 
Plasma (HHP) was used as the negative control. Mean absorbance was calculated from each experiment 
performed in duplicate and on two independent occasions.
www.nature.com/scientificreports/
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Dynabeads. While IgG eluted from the blank beads and HHP samples did not show neutralization activity against 
any of the tested pseudoviruses (Supporting Table S3 and Fig. S4), polyclonal IgG eluted from NAB122 exhibited 
moderate neutralization breadth and potency against all the tested tier-2 cross-clade pseudovirus panel (Table 9). 
NAB069 neutralized all viruses except RHPA pseudovirus (subtype B), indicating the presence of MPER specific 
bNAbs in these two samples.
Figure 3. Identification of CD4-binding site antibodies. (A) ELISA with RSC3 and RSC3∆ 371I/P363N 
recombinant proteins. 12 BCN plasma samples were tested at a dilution of 1:100 to screen for the presence of 
CD4 binding site directed antibodies. Four of the 12 BCN plasma samples tested demonstrated significantly 
stronger binding to the wild type RSC3 protein as compared to the mutant protein. (B) RSC3 and RSC3∆ 371I/
P363N specific antibodies were eluted from four BCN plasma samples which revealed the presence of CD4 
binding site targeting antibodies (NAB033, NAB059, NAB063 and NAB069) using tosyl activated MyOne 
Dynabeads. ELISA was again performed with eluted IgG antibody (concentration 10 to 0.0001 μ g/ml) with 
RSC3 and RSC3∆ 371I/P363N recombinant proteins at 2 μ g/ml. Monoclonal antibodies VRC01, VRC03, B12 
and 3BNC117 were used as positive controls and HHP as negative control. (C) Neutralization titer (IC50) assay 
performed with eluted IgG antibody (concentration 10 to 0.0001 μ g/ml) against  four pseudoviruses and one 
mutant (JR-FL D279A). VRC01 and b12 MAbs were used as positive control bNabs against CD4BS and MuLV, 
as negative control.
www.nature.com/scientificreports/
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Discussion
In the recent years, enormous amount of research has been focused on the identification of broadly neutralizing 
antibodies from many parts of the world15–18 and several broad and potent neutralizing antibodies have been 
identified from HIV-infected individuals19–23. However, Indian research in this line have been limited to a few 
groups24–27. Given the preponderance in the global epidemic of the subtype C virus which is also the predomi-
nant circulating subtype in the Indian population, more studies in HIV-1 subtype C infected individuals would 
possibly lead to the identification of more potent bNAbs and novel epitopes that can be exploited for HIV vaccine 
research.
In the present study, plasma of 88 asymptomatic, ART naïve HIV-1 subtype C infected individuals from a 
South Indian HIV-1 cohort were screened for the presence of bNAbs. Twelve of the 88 samples (14%) strongly 
neutralized > 90% of the tier 1, 2 and 3 viruses tested and have been categorized in this study as broadly 
cross-clade neutralizing (BCN) samples. Previous studies have also reported that about 10-30% of HIV-1 infected 
individuals develop bNAbs sometime during the course of infection28,29. Interestingly, we observed that all the 
BCN samples identified in our study neutralized subtype C pseudoviruses very strongly, endorsing recent reports 
on strain specific neutralization potential of NAbs30,31.
The BCN samples identified in the present study were characterized for their potency by determining their 
ID50 titers against seven difficult-to-neutralize tier-3 pseudoviruses. Four samples (NAB001, NAB059, NAB063 
and NAB069) demonstrated high potency of neutralization, with GMT > 600; one sample (NAB059) had a GMT 
> 1100. The remaining six samples exhibited moderate potency, with GMT ranging from 100 to 400. Our findings 
are in agreement with previous reports that approximately 1% of the HIV-1 infected individuals may develop 
antibodies with strong potency and great breadth of neutralization28.
PepScan analysis showed that most of the samples had antibodies that bound strongly to the V3 and ID 
regions of gp160. Similar observations were also made by other groups of investigators24,32 who reported that 
most of the HIV-1 infected individuals harbour such antibodies, but these are generally non-neutralizing 
Samples ID
Mean absorbance at 450 nm Binding Difference between 
RSC3 and RSC3Δ371I/
P363N proteins P value
% of RSC3 binding 
antibodies in the 
BCN plasma samples
RSC3 
protein
RSC3D371I/
P363N protein
NAB001 0.214 0.267 − 0.053 P > 0.05 ND
NAB004 0.154 0.147 0.007 P > 0.05 ND
NAB016 0.1585 0.145 0.0135 P > 0.05 ND
NAB033 0.361 0.161 0.2 P < 0.05 55
NAB046 0.268 0.312 − 0.044 P > 0.05 ND
NAB059 1.089 0.6515 0.437 P < 0.001 40.2
NAB062 0.2805 0.1945 0.086 P > 0.05 ND
NAB063 1.87 1.265 0.6055 P < 0.001 32.3
NAB065 0.084 0.153 − 0.069 P > 0.05 ND
NAB069 2.31 0.2085 2.102 P < 0.001 91
NAB120 0.1475 0.1615 − 0.014 P > 0.05 ND
NAB122 0.237 0.1525 0.0845 P > 0.05 ND
Control (HHP) 0.075 0.079 − 0.0045 P > 0.05 NA
Table 3.  Identification of CD4BS directed antibodies in BCN plasma samples. Samples having CD4BS 
directed antibodies are highlighted in bold. p < 0.05 is considered significant. N.D., Not Detectable; N.A., Not 
Applicable.
Monoclonal antibody/
polyclonal IgG
IC50 μg/ml
Name of pseudoviruses
Tier-2 subtype B Tier-2 subtype C Tier-3 subtype B control virus
JR-FL WT JR-FL D279A DU422 CAP45.2.00 PVO-4 MuLV
VRC01 0.019 4.34 > 10 0.238 0.12 > 10
b12 0.02 0.10 0.08 0.31 > 10 > 10
NAB069 1.18 > 10 > 10 9.0 6.8 > 10
NAB063 1.28 > 10 > 10 > 10 5.2 > 10
NAB059 9.1 > 10 > 10 > 10 > 10 > 10
NAB033 > 10 > 10 > 10 > 10 9.0 > 10
HHP > 10 > 10 > 10 > 10 > 10 > 10
Table 4.  Neutralization activity of RSC3-specific IgG eluted from four BCN plasma samples with CD4BS 
specificity. IC50 values < 0.5 μ g/ml are in italics, values between 0.5–10 μ g/ml are in bold format and values > 
10 μ g/ml are normal format.
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in nature. Two samples (NAB016 and NAB059) showed reactivity with the Kennedy epitope (KE; 
PRGPDRPEGIEEEGGERDRDRS)33 present in the transmembrane (TM) region of gp41 (amino acids 731 to 752 
as on HXB2)34. This region is known to contain three epitopes PDRPEG (KE1), IEEE (KE2) and ERDRD (KE3), 
and antibodies to these epitopes are thought to bind to HIV-1 particles after they attach themselves to the cell 
receptors35. In general, the antibody response to the Kennedy epitopes in HIV-1 infected individuals is thought to 
be very weak36. Interestingly, the Indian reference strain, 93IN101 (pIndie), has amino acid substitutions in KE1 
and KE3, resulting in an altered amino acid composition of the epitopes (PDRLGR and EQDKDR respectively). 
NAB016 and NAB059 exhibited a high binding affinity to PDRLGR, suggesting that changes in KE1 of subtype 
C has relevance to improved binding antibody response, which might or might not translate to inactivation of 
HIV-1 by neutralization. MPER comprises the last 23 residues of the gp41 ectodomain. Several well characterized 
Figure 4. Neutralization sensitivity assay to detect Glycan-dependent antibodies. (A) Neutralization 
curves of BCN plasma samples against HIV-1 subtype C tier-2 pseudoviruses Du156.12 WT and mutants with 
substitutions at glycan positions 160 and 332. Neutralization titration assay was performed with BCN plasma 
samples in duplicates at dilutions 1:10 to 1:100000 on two independent occasions. (B) Sensitivity analysis of 
JR-FL wild type (WT) and E168K mutant in the selected BCN plasma samples for the PG9/PG16 recognizing 
epitopes. (C) Neutralization activity against glycan positions at N156 and N160 in the JR-FL E168K mutated 
strain for the confirmation of PG9/PG16 bNAbs. The assays were performed in duplicates on two independent 
experiments with dilutions ranging from 1:20 to 1:43740.
www.nature.com/scientificreports/
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NAbs like 2F5, Z13e1, 4E10 and 10E8 bind to linear epitopes in MPER17,37. In our study, three samples (NAB069, 
NAB120 and NAB122) showed binding reactivity to MPER peptides.
The CD4 receptor on the target cell plays a major role in viral entry by interacting with the CD4 binding site 
present on the HIV envelope. Before 2009, b12 was the only CD4BS bNAb that was identified. However, since 
2009, several CD4BS bNAbs with greater breadth and potency of neutralization than b12 have been isolated from 
HIV-1 infected individuals, such as VRC01-03, VRC23, NIH45-46, 3BNC117, etc38, and two of these, VRC01 
and 3BNC117, are currently being tested for use as therapeutic vaccines against HIV-139,40. We first tested plasma 
binding activity to the wild type RSC3 protein which selectively binds to VRC01-like CD4BS specific bNAbs, and 
a mutant form of the protein which shows decreased binding to CD4BS bNAbs25,41. We identified four samples 
containing VRC01-like CD4BS antibodies, as demonstrated by their ability to preferentially bind to the RSC3 WT 
protein but not to the mutant form. In order to determine the neutralizing potential of the CD4BS specific anti-
bodies in these samples, we eluted IgG from the plasma and tested them in a neutralization assay with tier-2 and 
tier-3 pseudoviruses. Two of the four samples, NAB069 and NAB063, exhibited strong neutralization of the tier-2 
virus JR-FL WT and tier-3 HIV-1 subtype B pseudovirus PVO-4 but diminished neutralization of JR-FL D279A, 
just like VRC01. These observations provide clear evidence to show that these samples contain CD4BS specific 
antibodies with neutralization ability. Our findings mirror those of Landais et al.42 and others that although RSC3 
binding activity may be found in some HIV-1 infected individuals42, RSC3 reactive antibodies mediating broad 
neutralization were only detected in very few individuals. A major limitation of the RSC3 binding approach as 
observed by previous investigators (Walker et al.14) is that some CD4BS bNAbs may not bind to the RSC3 protein, 
necessitating the use of additional recombinant gp120 (rgp120) core molecules14,43. However, we could not per-
form further experiments with rgp120 adsorbed antibodies due to insufficient sample volume.
It is well known that HIV uses glycan shields to escape attack by the host immune system. The glycan shields 
hinder accessibility to the neutralizing antibody binding sites. Thus, identification of bNAbs that target some of 
Sample ID
ID50 Fold change*
DU156WT N160K N332A N160K N332A
NAB016 811.6 645.7 513.7 1.3 1.6
NAB033 623.8 580 310.9 1.1 2.0
NAB046 1827 7852 556.6 0.2 3.3
NAB059 1316 5500 970.7 0.2 1.4
NAB062 6400 255.8 263.6 25.0 24.3
NAB063 726.5 775 883.3 0.9 0.8
NAB065 468.2 609.4 184.4 0.8 2.5
NAB069 3328 1675 940 2.0 3.5
HHP < 10 < 10 < 10 NA NA
Table 5.  Neutralization activity of BCN samples against DU156 pseudovirus with mutations in 
peptidoglycans targeted by the PG9/PG16 and PGT series of bNAbs. *Fold change = ID50 of HIV-1DU156WT/
ID50 of HIV-1DU156 mutant. Values with fold changes ≥ 3.0 are highlighted in bold format. NA, Not Applicable.
Sample ID
ID50 Fold increase in the sensitivity@
JR-FL WT JR-FL E168K E168K
NAB016 1008 5003 4.96
NAB033 1008 4999 4.96
NAB062 1232 6308 5.12
NAB069 922.5 12401 13.44
Table 6.  Neutralization activity against HIV-1JR-FL WT and E168K mutant pseudoviruses. @The fold change 
calculated by ID50 of JR-FL E168K/ID50 of JR-FL WT. Increased neutralization sensitivity values > 3.0 fold are 
highlighted in bold format.
Sample ID
ID50 Fold change#
JR-FL E168K E168K/N156K E168K/N160K E168K/N156K E168K/N160K
NAB016 5003 1674 1000 2.99 5.00
NAB033 4999 1807 2614 2.77 1.91
NAB062 6308 1605 1584 3.93 3.98
NAB069 12401 4548 3342 2.73 3.71
Table 7.  Neutralization activity of the selected BCN plasma samples against HIV-1JR-FL E168K and double 
mutated pseudoviruses. #The fold change calculated by ID50 of JR-FL E168K/ID50 of JR-FL E168K mutant. 
Values ≥ 3.00 are highlighted in bold format.
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the critical glycans on the HIV envelope could pave the way for designing an effective vaccine against HIV44. 
Potential N-linked glycans at positions 160 and 332 on the HIV envelope are known to be very crucial for the 
binding of glycan dependent antibodies belonging to the PG9/PG16 and PGT series, respectively13,45. We evalu-
ated the BCN samples identified in our study for the presence of potential N-linked glycan dependent antibodies. 
For this purpose, we performed neutralization assay with a subtype C pseudovirus, DU156WT, and its mutant 
forms DU156N160K and DU156N332A. Studies have shown that viruses, mutated at position 160 (V2 loop) 
escape neutralization by PG9/PG16 antibodies26,46. We identified four samples (NAB016, NAB033, NAB062 and 
NAB069) that strongly neutralized DU156WT but showed reduced levels of neutralization of the mutant virus 
DU156N160K, suggesting that these samples are likely to contain PG9/PG16 like antibodies. One of the four 
samples, NAB062, showed a 25-fold reduction in neutralization of DU156N160K as compared to DU156WT, 
indicating the strong specificity of the antibodies present in this sample to this epitope. In addition, these four 
samples also demonstrated strong neutralization of the JR-FL E168K mutant pseudovirus as compared to WT 
JR-FL pseudovirus, providing further support for the PG9/PG16-like specificity of the antibodies in these sam-
ples. This is due to the presence of glutamic acid (E) at 168 position in JR-FL that masks the exposure of aspar-
agine (N) glycans at positions 156 and 160 thereby abrogating the binding of PG9/PG16 like antibodies to this 
epitope13. We found a further reduction in the neutralization activity of the plasma on the double mutants (JR-FL 
E168K N156K and JR-FL E168K N160K) as compared to the single mutant, providing further proof to document 
the presence of PG9/PG16 like bNAbs in these samples.
Interestingly, two of the samples (NAB033 and NAB069) that showed PG9/PG16-like neutralization activity 
also contained CD4BS antibodies as seen in the previous experiment. Four other samples (NAB046, NAB059, 
NAB063 and NAB065) showed a higher level of neutralization of the mutant virus DU156N160K, than the WT 
virus indicating the possibility that these samples contain NAbs that are independent of glycan at N160 but target 
other regions of the HIV-1 Env.
The PGT series of antibodies (PGT 121-like and PGT128-like) bind to the glycan site N332 from various 
angles and neutralize HIV-138,47. To identify if antibodies with similar specificities were present in any of our 
BCN samples, we analyzed the plasma for neutralization activity against the subtype C virus, DU156WT and 
mutant DU156 N332A pseudovirus. Seven BCN samples neutralized DU156WT indicating the presence of anti-
bodies belonging to the PGT series. Similar observations of a high frequency of N332 glycan-dependant anti-
bodies among HIV-1 subtype C infected individuals from sub-Saharan Africa was recently reported by Landais 
et al.42. Of the seven samples, one sample NAB062, showed 24.3 folds reduction in neutralization of the mutant 
as compared to the WT. Two other samples, NAB046 and NAB069, also showed a reduction of 3.3 and 3.5 fold in 
neutralization of the mutant as compared to WT virus. This suggests the possibility that the above three samples 
could contain antibodies similar to the PGT series of antibodies. To our knowledge, this is the first study from 
India to demonstrate the presence of PGT series of bNAbs among HIV-1C infected individuals from the country. 
Chimera MPER Sequence@
Neutralization
MAbs IC50*(μg/ml) Plasma ID50 (1/dilutions)
2F5 4E10 Z13e1 240-D NAB069 NAB120 NAB122
7312 A NMYELQKLNSWDVFGNWFDLASWVKYIQYGVYIV > 10 > 10 > 10 > 10 < 20 < 20 < 20
C1 (clade B) NMYELLALDKWASLWNWFDITKWLWYIKYGVYIV 0.016 0.0017 0.08 > 10 5,074 < 20 2,660
C1C (clade C) NMYELLALDSWKNLWNWFDITKWLWYIKYGVYIV > 10 0.018 0.07 > 10 12,960 < 20 165.5
C6 NMYELQKLNSWDVFGNWFDITSWIKYIQYGVYIV > 10 0.013 > 10 > 10 2,504 < 20 248.1
C7 NMYELQALDKWA VFGNWFDLASWVKYIQYGVYIV 0.07 > 10 > 10 > 10 < 20 < 20 < 20
Table 8.  Identification of MPER specific neutralizing antibodies. @HIV-1 MPER fragment substituted in 
the HIV-2 7312A virus. *Neutralization assay was performed with monoclonal antibodies 2F5, 4E10, Z13e1 as 
positive control and 240-D as negative control. Plasma ID50 was calculated against MPER grafted HIV-2 7312A 
viruses. The sequence carried by the MPER of each of the constructs is indicated in the second column. Mutated 
residues are indicated in bold (subtype B) and italic (subtype C). IC50 (μ g/ml) formatted as <10; 1–5; > 10. ID50 
(dilutions) formatted as < 20; 21–500; > 500.
polyclonal IgG eluted 
by MPER peptide
IC50 μg/ml
Name of pseudoviruses
Tier-2 subtype B Tier-2 subtype C control virus
JR-FL RHPA CAP210 pIndie MuLV
NAB069 14.16 > 40 13.6 9.2 > 40
NAB122 14.80 14.40 16.0 10 > 40
HHP > 40 > 40 > 40 > 40 > 40
Table 9.  Neutralization activity of MPER-specific IgG against tier-2 pseudovirus panels. Neutralization 
titer (IC50) assay was performed with IgG antibody (concentrations 40 to 0.0004 μ g/ml) eluted using MPER-
peptide coated tosyl activated MyOne Dynabeads against four HIV-1 pseudoviruses and MuLV IC50 values  
< 20 μ g/ml are shown in bold format and values > 20 μ g/ml are shown in normal format.
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Of special interest, we noticed that sample NAB069 had antibodies with multiple specificities, such as CD4BS, V2 
glycans and V3 glycan.
The three samples (NAB069, NAB120 and NAB122) which showed reactivity to MPER-specific peptides in 
the PepScan analysis were analyzed for neutralization potential using HIV-2/HIV-1 MPER chimera pseudovi-
ruses. NAB069 was found to strongly neutralize both subtype B and C chimeric viruses, while NAB122 neutral-
ized them weakly. We further evaluated the neutralization ability of IgG eluted from these two samples for their 
neutralization ability, and found them to show moderate neutralization breadth and potency against majority 
of the tier-2 cross-clade pseudoviruses confirming the presence of MPER specific bNAbs in these samples. Our 
results are in agreement with the previous reports that NAbs directed against HIV-2/HIV-1MPER have moderate 
breadth and potency of neutralization against HIV-1 pseudoviruses3,14,28,48. Since the MPER peptide is known to 
play a major role in the fusion of viral and host cell membranes49, our findings encourage further characterization 
of antibodies from these two samples.
In summary, our study has identified broad and potent neutralizing antibodies in plasma of a subset of HIV-1 
infected individuals from India. Four of the BCN samples had neutralizing activity with binding specificity to 
more than one vulnerable site on the HIV-1 Env (Table 10). One sample, NAB069, was found to have neutraliza-
tion activity with binding specificity to all the four vulnerable sites on the HIV-1 Env, suggesting that this sample 
is worthy of further investigation and characterization. A few other investigators have also reported the identifi-
cation of bNAbs targeting multiple vulnerable sites on the HIV envelope from a single donor14,48,50–52, but to our 
knowledge, this is the first study from India that has identified second generation broad cross clade neutralizing 
antibodies belonging to the CD4BS, PG9/PG16, PGT series and MPER in HIV-1C infected individuals. Further 
work is ongoing to isolate and characterize monoclonal antibodies from a few of these samples.
Methods
Ethics Statement. The study was approved by the Institutional Ethics Committee of the National Institute 
for Research in Tuberculosis (TRC IEC No: 2011001) and all experiments were performed in accordance with 
relevant guidelines and regulations. Sample collection was done after obtaining written informed consent from 
the study participants.
Study population and sample collection. A total of 101 HIV-1–infected subjects attending the ART 
Centre at the Kilpauk Medical College and Hospital, Chennai, India, during the period April 2011 to September 
2012, were recruited for the study. All study subjects were asymptomatic and naïve to ART at the time of sample 
collection. Fifteen milliliters of venous blood was collected in K3-EDTA treated blood collection tubes. Plasma 
was separated by centrifugation at 300 g and stored as 1 ml aliquots at − 80 °C until use. The plasma samples were 
heat inactivated at 56 °C for 1 hour before use.
Production and titration of Pseudoviruses. A panel of 18 pseudoviruses belonging to different clades 
and all 3 tiers were selected from the standard panel of pseudoviruses obtained from NIH AIDS Reagent pro-
gram, and used to screen plasma of HIV-1-infected individuals for the presence of bNAbs. In addition, single res-
idue mutant pseudoviruses (DU156 N160K, DU156 N332A) and chimeric viruses (7312A, C1, C1C, C6 and C7) 
were obtained as a kind gift from Dr. Lynn Morris (NICD, Johannesburg) and Dr. Jayantha Battacharya (THSTI, 
India), JR-FL WT plasmid from Muzafar Jan and Dr. Sunil Arora (PGI-Chandigarh, India), JR-FL E168K and its 
mutants N156K and N160K as well as  MuLV plasmids from Dr. Raghavan Varadharajan (IISc, Bangalore, India). 
Sample ID
Linear pepscan* RSC3 and RSC3Δ371I/P363N Proteins*
Mutated pseudovirus$
Specificity@
Mutated in Du156.12 WT
HIV-2/HIV-
1chimera 
V1 V2 V3 ID MPER MyOne -elute-ELISA
Neutralization 
assay# N160K N332A MPER
NAB001 ND ND ND ND ND − NA ND ND NA
NAB004 − − + + + + − − NA ND ND NA
NAB016 − − + + + + + − − NA + + NA Multiple specific
NAB033 − − + + + + + − + + + + + + NA Multiple specific
NAB046 − − + + + + − − NA − + + NA
NAB059 − − + + + + − + + − − NA
NAB062 − − + + + + + + − − NA + + + + + + NA Multiple specific
NAB063 − − + + + + + − + + + + + − − NA
NAB065 − − + + + /− − − NA − + + NA
NAB069 − − + + + + + + + + + + + + + + + + + + + Multiple specific
NAB120 − − + + + + + + + − NA ND ND − 
NAB122 − − + + + + + + − NA ND ND + 
Table 10.  Summary of neutralization activity of the 12 BCN plasma samples. *OD at 450 is < 0.1 = − , 
0.1–1.0 = + , 1.0–2.0 = + + , > 2 = + + + . $Neutralization titer ID50 less than 60 = − . 61–200 = + , 201–500 = + 
+ , > 500 = + + + . NA- Not Applicable, ND- Not Done. #IC50 values < 0.5 μ g/ml are represented as + + + , values 
between 0.5–5 μ g/ml as + + , values > 5 μ g/ml as + and values > 10 μ g/ml as − . @Neutralization analysis on 
HIV-1 cross clade and mutated pseudoviruses are considered for the determination of specificity.
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Pseudo viruses belonging to clades A, B, C, A/E and A/G, RSC3 WT and RSC3 Δ 371I/P363N recombinant pro-
teins were obtained from the NIH AIDS Reagent Program. Pseudoviruses were prepared by co-tranfection of 
pEnv and pSG∆ Env back bone plasmid into 293T cells using standard Calcium Phosphate method and titrated 
on TZM-bl cells53,54. Neutralization potential of the plasma samples was determined based on an observed reduc-
tion in luciferase gene expression after a single round of infection in TZM-bl cells with env-pseudotyped viruses 
as described53,54. Murine leukemia virus (MuLV) was used as a control virus.
Peptide – binding antibody ELISA. Fifteen amino acid long linear peptides with 11 amino acid over-
lap spanning the entire length of gp160 of the Indian subtype C virus 93IN101 were synthesized commercially 
(Infinity Biotech and Resource Inc., PA). The peptides were adsorbed onto 96-well ELISA immuno maxisorp 
plates (Thermo Fisher) at a concentration of 5 μ g/ml in 100 mM NaHCO3, pH 9.6, by overnight incubation at 
4 °C and ELISA was performed as described previously55 to map the epitope specificity of samples demonstrating 
good breadth and potency of neutralization. Each experiment was repeated three times. Healthy Human Plasma 
pool (HHP) was included as the negative control in all experiments. The samples were subsequently tested in an 
ELISA with recombinant proteins RSC3 and RSC3∆ 371I/P363N to look for the presence of CD4 binding site 
(CD4BS) antibodies.
Protein-paramagnet bead coupling, adsorption and elution of RSC3- specific antibodies. 
Paramagnetic polystyrene, Tosylactivated MyOne Dynabeads (Life Technologies) were coupled with recombinant 
HIV-1 RSC3 and double mutant RSC3Δ 371I/P363N proteins or pIndie MPER peptide as per the manufacturer’s 
instructions. Briefly, 0.1 mg of protein or 1 mg of MPER peptide was coupled to 0.50 mg or 5 mg of tosylacti-
vated magnet MyOne Dynabeads respectively. Coupling was done at room temperature (RT) in a total volume 
of 1.25 ml in coupling buffer (0.1 M sodium borate buffer [pH 9.5] with 1 M ammonium sulfate) with gentle 
rocking for 48 hours. The Dynabeads and bound protein were separated from the coupling buffer with a mag-
net and resuspended in 5 ml of blocking buffer (PBS [pH 7.4] containing 0.5% [wt/vol] bovine serum albumin 
[BSA] and 0.05% Tween 20) for an additional 48 hours. The blocking buffer was removed by aspiration, and the 
protein-coupled Dynabeads were washed two times with 5 ml of wash buffer (PBS [pH 7.4] containing 0.1% BSA 
and 0.05% Tween 20). The beads were then resuspended in 0.5 ml of storage buffer (PBS [pH 7.4] supplemented 
with 0.1% BSA, 0.05% Tween 20 and 0.02% sodium azide + protease inhibitors) and stored at 4 °C. On the fol-
lowing day, the protein-coupled beads were washed three times with Dulbecco modified Eagle medium (DMEM) 
containing 10% fetal bovine serum (FBS) and incubated in DMEM containing 10% FBS at room temperature 
for 30 minutes to block nonspecific binding to the beads. Samples exhibiting strong neutralization activity were 
diluted 1:50 in DMEM containing 10% FBS, and 1 ml of the diluted plasma was incubated with 0.5 ml of beads at 
room temperature for 30 minutes. This step was repeated three times for the better removal of antibodies. Beads 
coupled with RSC3 or MPER-specific antibodies were stored in PBS containing 0.2% BSA and 0.02% sodium 
azide at 4 °C. The remaining plasma was centrifuged three times at 16,100 × g for 5 minutes each time to remove 
any residual Dynabeads and used subsequently for ELISA and neutralization assays. BSA-coated beads or blank 
beads were used as negative controls. The protein-coupled beads were washed three times with PBS containing 
500 mM NaCl and once with PBS, and the antibodies were eluted by stepwise decrease in pH. First, the beads 
were mixed with 100 mM glycine-HCl elution buffer (pH 2.7) for 30 seconds. The beads were then centrifuged 
for 30 seconds and held in place at the bottom of the tube with a magnet. The acid-eluted solution containing IgG 
was quickly removed and placed in a separate tube containing 0.5 ml of 1 M Tris (pH 9.0) buffer to reach pH 7.0 to 
7.4. This process was repeated three times. The eluted IgG was diluted in DMEM and concentrated over a 30-kDa 
Centricon plus filter (Millipore Corp.). Subsequently, the same procedure was performed on the beads at an elu-
tion pH of 2.2 to recover any IgG resistant to elution at pH 2.7. The IgG fractions recovered by both acid elution 
steps were combined and the concentration of the combined IgG fractions was measured using nanodrop tech-
nology (Thermofisher). The IgG was further characterized by ELISA using RSC3 protein and its double mutant 
RSC3Δ 371I/P363N. Known monoclonal neutralizing antibodies (MAbs) VRC01, VRCO3, b12 and 3BNC117 
that bind specifically to the CD4BS were used as positive controls.
Virus Neutralization assay. Neutralization potential of plasma samples was evaluated using the standard 
neutralization assay54. Briefly, TZM-bl cells were infected with the pesudoviruses in the presence or absence of 
plasma. After 48 hours, 100 μ l of BriteLite (PerkinElmer) substrate was added to the wells. 100 μ l of supernatant 
was transferred to a solid opaque plate and luminescence was measured as relative luciferase units (RLU) using 
the Vector 3 luminometer (Perkin Elmer). Initial neutralization screening assays were performed at a plasma 
dilution of 1:10 dilution. Subsequently, for the determination of IC50/ID50 values, serial dilutions of the plasma 
samples ranging from 1:20 to 1:43,740 or 1:10 to 1:100,000 were used. Anti-glycan and anti-MPER specific neu-
tralization activity was evaluated using Du156WT, Du156N160K, Du156N332A, JR-FLWT, JR-FL E168K, JR-FL 
E168K N156K, JR-FL E168K N160K and HIV-2 7312A, HIV-2/HIV-1 MPER chimeric constructs. Polyclonal IgG 
eluted from plasma samples using tosyl activated MyOne Dynabeads coupled with RSC3 protein was tested in a 
neutralization assay with JR-FL WT, JR-FL D279A, DU422, CAP45.2.00 and PVO-4 pseudoviruses for evalua-
tion of CD4BS specificity. Further, polyclonal IgG were eluted from plasma samples using tosyl activated MyOne 
Dynabeads coupled with MPER peptide and neutralization ability of these Abs was determined against a tier-2 
pseudovirus panels (JR-FL, RHPA, CAP210 and pIndie) for evaluation of MPER specificity.
Statistical analysis. Statistical analysis was performed using the software Graphpad prism 5.0 for determi-
nation of ID50 values through a dose-response curve fit with non-linear regression. Significance was calculated 
using t-test. P < 0.05 was considered statistically significant.
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